Myofascial Release in Patients with Chronic Obstructive Pulmonary Disease

Effects of Myofascial Release in Patients with Chronic Obstructive Pulmonary Disease: a Randomized Clinical Trial

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04260243

Acronym

MFR-COPD

Enrollment

Registered

2020-02-07

Start date

2026-03-31

Completion date

2027-06-30

Last updated

2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Copd

Brief summary

The main objective of this study is to assess the effects of a myofascial release protocol in patients with chronic obstructive pulmonary disease (COPD).

Detailed description

So far, there are no previous studies that analyze the effects of a myofascial relaxation protocol applied to the diaphragm within the respiratory rehabilitation treatment in patients with chronic obstructive pulmonary disease. Aim: The main objective of this study is to assess the effects of a 3 weeks myofascial release protocol applied to the diaphragm on respiratory parameters in patients with chronic obstructive pulmonary disease. Design: Randomized clinical trial

Interventions

OTHERExperimental-Myofascial + Respiratory rehabilitation

6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)

OTHERSham Myofascial + Respiratory rehabilitation

6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* COPD; * Forced expiratory volume in the first second (FEV1) \< 80%; * FEV1/Forced vital capacity (FVC) \< 70%; * Maximal inspiratory pressure (MIP) \< 70%.

Exclusion criteria

* Recent (6 months) spine or abdominal surgery; * Allergic status of any kind; * systemic diseases (rheumatic, infectious conditions, febrile state, vascular alterations, endocrine diseases including diabetes, metabolic, and neoplastic syndromes); * neuromuscular or neurological injuries; * previous myofascial release treatment.

Design outcomes

Primary

Measure	Time frame	Description
Quality of life measured with the Chronic Obstructive Pulmonary Disease Assessment Test: Score	3 weeks	Score (0-40) higher scores mean a worse outcome.

Secondary

Measure	Time frame	Description
6 Minutes Walking Test	3 weeks	Maximum distance reached

Contacts

Primary ContactMARÍA DOLORES ARGUISUELAS, PhD

doloresarguisuelas@uchceu.es961369000

Backup ContactJUAN FRANCISCO L PÁRRAGA, PhD

juanfran@uchceu.es618055092

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026